FindTrial
Sign In

Construction of molecular signature combined with clinical feature for prediction of response to neoadjuvant chemotherapy in patients with breast cancer

Construction of molecular signature combined with clinical feature for prediction of response to neoadjuvant chemotherapy in patients with breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016763
Enrollment
Unknown
Registered
2018-06-22
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Sensitive Group:No
Insensitive Group:No

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Stage II-III breast cancer who received anthracycline-taxane-based neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Neoadjuvant chemotherapy regimens was not anthracycline-taxane-based

Design outcomes

Primary

MeasureTime frame
Miller and Payne system;—

Countries

China

Contacts

Public ContactHong Bu

West China Hospital, Sichuan University

hongbu@scu.edu.cn+86 028-8516-4034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026